SLC39A9 and infection: Furthermore, our findings revealed that recombinant SLC39A9 could inhibit EBOVΔVP30-EGFP infection in a dose-dependent manner, whereas an unrelated Varicella-Zoster Virus (VZV) glycoprotein E (VZV gE) showed no such effect (Fig 5E).